Total Voting Rights
Hemogenyx Pharmaceuticals plc announced on 30 January 2026 that its total issued share capital comprises 6,041,255 ordinary shares of 1p each, with no shares held in treasury, resulting in a total of 6,041,255 voting rights. This figure serves as the denominator for shareholders to determine notification requirements under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules regarding their interests in the company's share capital.
Select text to share a quote on X · sign in to keep highlights & notes in your HEMO notes
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 30 January 2026 consists of 6,041,255 ordinary shares of 1p each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 6,041,255.
The figure of 6,041,255 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.